Segment Information (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of significant segment expenses

In addition to the significant expense categories included within consolidated net income presented on the Company's Consolidated Statements of Operations, see below for disaggregated amounts that comprise research and development expenses:


	Year Ended December 31,
(In millions)	2025		2024		2023
Direct research and development expenses(a)	$	1,758.1	$	1,588.8	$	1,295.6

Indirect research and development expenses:
Payroll and benefits	1,800.8		1,681.7		1,537.0
Lab supplies and other research and development costs	258.2		241.5		210.6
Occupancy and other operating costs	635.4		614.9		518.2
Total indirect research and development expenses	2,694.4		2,538.1		2,265.8

Clinical manufacturing costs	1,391.2		1,195.9		1,053.9

Priority review voucher	155.0		—		—

Reimbursement of research and development expenses by collaborators	(148.5)		(190.8)		(176.3)

Total research and development expenses	$	5,850.2	$	5,132.0	$	4,439.0

(a) Direct research and development expenses are comprised primarily of costs paid to third parties for clinical and product development activities, and the portion of research and development expenses incurred by our collaborators that we are obligated to reimburse

REGENERON PHARMACEUTICALS, INC. 10-K